Clinical trials: Neoplasm Circulating Cells
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Melanoma
TNF in Melanoma Patients Treated With Immunotherapy
This trial is a translational proof-of-concept, open-label, prospective cohort study of 60 patients aiming to identify the clinical markers and/or biomarkers associated with therapeutic response to immune checkpoints inhibitors…
- Trial name
- MELANFα (NCT03348891)
- Testing
- Tumor biopsy specimens and blood samples
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood.
- Trial name
- NCT04099290
- Testing
- Blood and tumor samples
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer, Metastatic Cancer
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
- Trial name
- IRSTB030 (NCT03381326)
- Testing
- blood and FFPE sample collection
- Where
- 9 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer
- Trial name
- NCT05420948
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
NSCLC
Circulating Fibrocytes in Non-small Cell Lung Cancer.
The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion of immunosuppressive fibrocytes, which are…
- Trial name
- NCT01998425
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma, Desflurane Adverse Reaction
Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor
To investigate the effects of perioperative anesthetic drugs propofol and desflurane on circulating tumor nucleic acids (CK7, ELF3, EGFR and EphB4 mRNA) in the blood of patients with liver cancer, so as to provide scientific…
- Conditions
- Hepatocellular Carcinoma, Desflurane Adverse Reaction, Propofol Adverse Reaction, Circulating Tumor Cells
- Trial name
- NCT05502458
- Testing
- Desflurane, Propofol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Recurrence, Metastasis
Prognostic Value of CTC in HNSCC Patients
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- CTCHNSCC01 (NCT01884129)
- Where
- Taiwan
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Stage IV Colorectal Cancer, Liver Metastases
Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. About 90% of CRC related deaths are due to metastatic spread-mostly to the liver and lungs.
- Conditions
- Stage IV Colorectal Cancer, Liver Metastases, Lung Metastases
- Trial name
- NCT01722903
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.
- Trial name
- NCT02418234
- Testing
- mutation detection, ARMS and ddPCR, ctDNA analysis
- Where
- China
- Volunteers
- 314 people
- Sponsor
- First People's Hospital of Hangzhou
Hepatocellular Carcinoma
Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
All consecutive patients with liver cirrhosis, with clinical and imaging features suggestive of Hepatocellular Carcinoma (HCC) attending the Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS) from February…
- Trial name
- NCT03162198
- Testing
- Cirrhosis with HCC, Cirrhosis without HCC
- Where
- India
- Volunteers
- 53 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood…
- Trial name
- DETECT III (NCT01619111)
- Testing
- standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Prof. Wolfgang Janni
Stage IIIB Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Circulating Tumor Cells in Lung Cancer
TITLE : Circulating tumor cells identification in advanced stage non-small cell lung cancer (CIRCUBRONCH) BACKGROUND : Circulating tumor cells identification is a new field of research in oncology, and some studies have been…
- Trial name
- CIRCUBRONCH (NCT01658332)
- Testing
- blood samples
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Central Hospital, Nancy, France
Non-small Cell Lung Cancer
ctDNA as a Biomarker for Treatment in Advanced NSCLC
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or…
- Trial name
- NCT05486988
- Testing
- Immunotherapy, Chemotherapeutic Agent, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fuzhou General Hospital
Non-small Cell Lung Cancer (NSCLC)
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC).
- Trial name
- NCT02380196
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Circulating Tumor Cell, Nasopharyngeal Carcinoma
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting…
- Conditions
- Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
- Trial name
- NCT04544969
- Testing
- cisplatin-based chemotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited.
- Trial name
- NCT07439328
- Testing
- Peripheral Blood Collection for CTC Isolation and Analysis
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Lymphoma, Large B-Cell, Diffuse
Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA
The aim of the project is to clarify whether DLBCL exhibits mutational diversity among different lymph node tumors in one and the same patient.
- Trial name
- NCT04763148
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Herlev Hospital
Melanoma, Melanoma Stage III
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Trial name
- NCT06199713
- Testing
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison